October 31st, 2022 / News Ubiquigent obtains exclusive license for UbiSite® technology to strengthen its specialist drug discovery services
July 5th, 2022 / News Ubiquigent appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board